Trials / Completed
CompletedNCT00764309
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the safety of Dasatininb in the treatment of scleroderma pulmonary interstitial fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dasatinib | Tablets, Oral, 100 mg, once daily, 6 months |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2010-06-01
- Completion
- 2011-04-01
- First posted
- 2008-10-02
- Last updated
- 2012-02-29
- Results posted
- 2012-02-29
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00764309. Inclusion in this directory is not an endorsement.